Condition: Refractory B-Cell Lymphoma · B-cell Lymphoma Recurrent · Sponsor: Instituto de Investigación Biomédica de Salamanca
The goal of this clinical trial is to to evaluate the safety and efficacy of TranspoCART19 in patients with relapsed/refractory B-lymphoma. The main questions it aims to answer are: Maximum tolerated dose (MTD) Response rates Participants will be treated with the investigational medicinal product and will be followed for 36 months.
This description comes directly from the study's public registry record.
Esperanza López_Franco, PhD · 923 291200 · uicec.coordinacion@ibsal.es
Fátima Macho Sánchez-Simón · 923 291200 · uicec.admon@ibsal.es
Always discuss trial participation with your own doctor first.
| Hospital Clínic | Barcelona, Barcelona, Spain | Not Yet Recruiting |
| Institut Català d'Oncologia Hospital | L'Hospitalet de Llobregat, Barcelona, Spain | Recruiting |
| Fundación Jiménez Díaz Hospital | Madrid, Madrid, Spain | Recruiting |
| Virgen de la Arrixaca University Hospital | El Palmar, Mur, Spain | Recruiting |
| Clínica Universidad de Navarra | Pamplona, Navarre, Spain | Recruiting |
| University Hospital of Navarra | Pamplona, Navarre, Spain | Recruiting |
| Salamanca University Health Care Complex | Salamanca, SALAMANCA, Spain | Recruiting |
| Virgen del Rocio Hospital | Seville, Sevilla, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06378190